Outcomes of cochlear implantation in 75 patients with auditory neuropathy

Background Cochlear implantation (CI) outcomes in patients with auditory neuropathy (AN) are variable, which hampers patients’ decisions on CI. Objective This study aims to assess the outcomes of CI in individuals diagnosed with AN and to examine the various factors that may influence the effectiveness of this intervention. Methods A total of 75 patients diagnosed with AN were included in the study. The hearing threshold, the score of categories of auditory performance (CAP), speech intelligibility rating (SIR), and speech audiometry were tested. Genetic testing was conducted by medical exome sequencing in 46 patients. Results After CI, the average aided hearing threshold for patients with prelingual and post-lingual onset was 38.25 ± 6.63 dB and 32.58 ± 9.26 dB, respectively; CAP score improved to 5.52 ± 1.64 (p < 0.001) and 6.00 ± 0.96 (p < 0.001), respectively; SIR score increased to 3.57 ± 1.22 (p < 0.001) and 4.15 ± 0.95 (p < 0.001), respectively. Maximum speech recognition ranged from 58 to 93% for prelingual onset patients and 43 to 98% for those with post-lingual onset. Speech outcomes of CI in cases with cochlear nerve (CN) deficiency were significantly poorer (p = 0.008). Molecular etiologies, including TWIST1, ACTG1, m.A7445G, and a copy-number variant (CNV) carrying ACTB, were related to AN here. Conclusion CI is a viable therapy option for patients with AN; CN deficiency might impact outcomes of CI.


Introduction
Auditory neuropathy (AN) or auditory neuropathy spectrum disorder (ANSD) is a specific type of sensorineural hearing loss characterized by the presence of otoacoustic emissions (OAE) and/or cochlear microphonics with the absent or abnormal auditory brainstem responses (ABR) (Moser and Starr, 2016).Nearly 9.85% of 1,025 children with sensorineural hearing loss were identified to have ANSD (Almishaal et al., 2022).
In patients with AN, the degree of hearing loss (HL) varies from mild to profound, and it can occur prelingually or post-lingually.In contrast, the hearing may be affected bilaterally or unilaterally.AN may occur simply or as part of some syndromes.Simultaneously, patients of AN may also have inner-ear malformations.Risk factors, including hyperbilirubinemia, infection, premature, ototoxic drug exposure, cochlear nerve (CN) deficiency, and congenital brain anomalies (Rajput et al., 2019;Natale et al., 2020;Liddle et al., 2022), are highly related to AN.
Many genes have been found as the molecular causes of AN (Moser and Starr, 2016;Shearer and Hansen, 2019), with hereditary patterns involving autosomal recessive, autosomal dominant, X-linked, and mitochondrial.More novel genes associated with AN are expected to be discovered, which would promote our insights into the pathogenesis of AN and guide the treatment and prevention of this disorder.Considering the treatment, cochlear implantation (CI) can benefit patients with AN (Sarankumar et al., 2018;Alzhrani et al., 2019).Studies have demonstrated that factors including the age of implantation, duration of cochlear, and genetic lesion sites could impact outcomes of CI (Daneshi et al., 2018;Shearer and Hansen, 2019).Speech performances in patients with AN receiving CI were variable (Harrison et al., 2015;Chaudhry et al., 2020), which traps the patients' decision on CI.
This study enrolled 75 unrelated patients with AN who received cochlear implantation.Outcomes of CI in patients were evaluated through auditory assessment, speech audiometry, and questionnaires, including categories of auditory performance (CAP) and speech intelligibility rate (SIR).Meanwhile, for 46 patients, medical exome sequencing was performed for genetic testing.The molecular etiology of this specific patient subgroup was thoroughly elucidated.Furthermore, examining candidate factors, including hereditary influences that may affect the IC outcomes of individuals with AN, was also assessed to provide more reliable information for the decision of the rehabilitation approach for AN.

Subjects
In this study, 84 patients diagnosed as AN and received CI in Chinese PLA General Hospital from 2010-08 to 2020-11 were enrolled.Exclusion criteria were: (1) having a tumor (e.g., acoustic neuroma), (2) severe cognitive abnormality hampering speech development, (3) otitis media, and (4) loss to follow-up.Finally, 75 subjects were included.The Ethics Committee of Chinese PLA General Hospital approved this study.It was conducted as per the Declaration of Helsinki.Written informed consent was obtained from the participants or the parents of the minors.

Audiology and speech recognition evaluation
Auditory brainstem responses (ABR), distortion-product otoacoustic emissions (DPOAE), cochlear microphonics, and tympanometry were conducted to diagnose AN.Pure tone audiometry (PTA) was used for auditory threshold determination in subjects >5 years old who could complete this testing; behavior audiometry was performed in subjects ≤5 years old, including strength vision audiometer (subjects >1 and ≤ 2.5 years old) and play audiometer (subjects >2.5 and ≤ 5 years old).ABR and auditory steady-state response (ASSR) were measured for patients who could not undergo the aforementioned auditory tests.The degree of hearing loss was determined by the average threshold at frequencies of 0.5, 1, 2, and 4 kHz or response thresholds in ABR.The level of HL was graded as mild (26-40 dB), moderate (41-55 dB), moderately severe (56-70 dB), severe (71-90 dB), and profound (>90 dB).To evaluate the hearing sensitivity pre-operation and post-operation, categories of auditory performance (CAP) were also used.
Hierarchic speech audiometry was estimated based on patients' age and their capability of hearing and speech.The Mandarin Early Speech Perception (MESP) test was performed for patients aged 2 to 5 years to evaluate the children's recognition of words.The Mandarin Pediatric Speech Intelligibility (MPSI) test was chosen for patients aged 3 to 6 years to assess the children's perception of sentences (Zheng et al., 2009a,b;Ji et al., 2015).Speech audiometry was performed to test Mandarin monosyllables, disyllables, and sentences in quiet for subjects who could complete this test (Ji et al., 2014).Additionally, speech intelligibility rating (SIR) was used to evaluate the communication ability before and after IC at least six months postoperation (Ji et al., 2015).

Imaging tests
In order to assess the condition of the inner ear and auditory nerve, a comprehensive diagnostic approach was employed, which included high-resolution computed tomography (CT) scanning of the temporal bone, magnetic resonance imaging (MRI) of the brain, and magnetic resonance hydrography (MRH) of the inner ear.

Genetic testing
The genetic cause of patients was identified through medical exome sequencing (Trio exome sequencing was performed for probands whose parents' DNA samples were available).The peripheral blood was obtained, and DNA was extracted according to the standard protocol.DNA sequencing (targeting 52.9 Mbp of the genome, covering the exons of 19,608 genes), bioinformatics analysis, and variant interpretation were performed following an earlier described protocol (Wu et al., 2022).Copy number variation was detected as described earlier (Baux et al., 2017), and the method of in-run correction and the Z-test analysis was applied in CNV calling.Candidate variants were confirmed by Sanger sequencing, while CNV was confirmed by real-time quantitative PCR.Variants were classified based on the American College of Medical Genetics and Genomics guidelines.Novel variants identified here were submitted to the ClinVar database with the accession number from SCV002568090 to SCV002568102.had post-lingual HL (>3 years old).Among this subgroup, the onset or awareness age of HL in 13 patients ranged from 3 to 16 years of age.Unilateral AN was identified in three cases, with sensorineural HL determined in the contralateral ear.The average implantation age was 2.67 ± 2.17 years for subjects with prelingual HL and 20.29 ± 8.44 years for patients with post-lingual HL.Bilateral implantation was conducted in eight cases with the same type of device (Table 1).
Based on imaging results, 10 patients had bilateral cochlear nerve (CN) deficiency, including hypoplastic CN and absent CN; two cases had a bilateral cochlear malformation, and another case had enlarged vestibular aqueduct (EVA) (Supplementary Table S1; Sennaroğlu and Bajin, 2017).

Auditory and speech assessments before cochlear implantation
Of the patients with prelingual HL (61 subjects), behavior audiometry was completed in 20 cases, with the average hearing threshold being 98.38 ± 16.28 dB for left ears and 102.56 ± 17.14 dB for right ears (Figures 1A,B).ASSR results of this patient subgroup (n = 56) are shown in Figures 1C,D, with the average hearing threshold being 81.48 ± 15.23 dB for left ears and 83.34 ± 15.40 dB for right ears.
For the remaining 14 cases with post-lingual onset, the average hearing threshold through PTA was 79.08 ± 15.11 dB for left ears and 74.83 ± 22.58 dB for right ears (Figures 1F,G).At the same time, maximum speech recognition scores ranged from 0 to 36% (n = 5) for this subgroup by speech audiometer, indicating profound speech disabilities.

Outcomes of cochlear implantation in patients caused by genetic etiologies
In this study, 46 patients (39 with the prelingual onset and seven with post-lingual onset) participated in genetic testing using high throughput sequencing.When only pathogenic or likely pathogenic variants were considered, molecular etiologies were identified in 25 patients (20 patients of prelingual onset and five cases of post-lingual onset), with two leading responsive genes being OTOF in 13 prelingual onset patients and AIFM1 in three cases of post-lingual hearing loss.Genetic testing results are presented in Table 3.

AIFM1
In three subjects (cases 46, 51, 68), simple hearing loss was identified to be caused by mutations in AIFM1.In case 46, the average hearing threshold improved from 78.25 dB to 40 dB, the CAP score increased from 0 to 3, and the SIR score improved from 1 to 5 after three years of operation.In case 51, the speech recognition score of monosyllables, disyllables, and sentences in quiet was 0, 0, and 0% before implantation.In comparison, the score was 82, 88, and 98%, respectively, after 1.5 years of implantation in the left ear.In patient 68, the CAP score increased from 2 to 5, and the SIR score increased from 1 to 3 after one year of implantation.

TIMM8A
Two mutations in TIMM8A were detected in patients 61 and 70, respectively.Case 61 was found to have progressive hearing     The maternal aunt of Proband 70 also had hearing loss with the same pathogenic variant as Proband, which was revealed when he was 30.Case 70 and his maternal aunt had no other obvious abnormalities.
After one year of implantation in the left ear, the average hearing threshold of case 70 improved from 91.25 dB to 36.25 dB, the CAP score increased from 0 to 6, and the SIR score rose from 1 to 3.

ATP1A3
For case 15, progressive hearing loss combined with tinnitus was noticed at nine years of age, and no other abnormality was reported.The mother of Proband was also affected by hearing loss combined with nystagmus and ataxia at three years old.A known pathogenic variant in ATP1A3 (p.Glu818Lys) (Han et al., 2017) was found in Proband and confirmed to be inherited from his mother.The average hearing threshold for this patient improved from 71.25 dB to 35 dB.The speech recognition score of vowel, consonant, disyllable, and tone was 72, 80, 70, and 72%, respectively by the MESP test; the SIR score increased from 1 to 3 after unilateral cochlear implantation of half a year.

TWNK
In case 22, compound heterozygote variants in the TWNK gene were detected.He walked unsteadily and fell quickly after three years old; both eyes had strabismus and astigmia when he was four years old and progressive hearing loss at half past five years old.He was later diagnosed as AN with profound hearing impairment.His speech, understanding, emotion management, and body development were delayed.The sibling of Proband had similar clinical manifestations and had the same compound heterozygote variants in TWNK.Accordingly, these two siblings were diagnosed with Perrault syndrome.For the Proband, after one year of implantation, the average hearing threshold improved from 98.75 dB to 38.25 dB, and vowel, consonant, disyllable, and tone recognition scores in the quiet field were 36, 36, 36, and 56%, respectively.In contrast, the speech recognition rate was 0% for all subtests before CI by the MESP test.The CAP score increased from 0 to 6, and the SIR score improved from 1 to 3 after two years of implantation.
Case 30 had congenital hearing loss combined with ovarian dysfunction, manifested as primary amenorrhea and undeveloped mammary gland.Compound heterozygote variants in the TWNK gene were also identified in this patient.The CAP score increased from 1 to 4, and the SIR score rose from 1 to 3 after two years of implantation.

TWIST1
Case 11 had congenital hearing loss and was later diagnosed as AN with profound hearing impairment.This patient had ptosis on the right eye, hypertelorism, skull shape asymmetry, and bilateral semicircular canal abnormalities.She had a pathogenic variant in the TWIST1 gene (rs104894054).Accordingly, the patient was diagnosed as having Saethre-Chotzen syndrome.The average hearing threshold improved from 102.5 dB to 35 dB, the CAP score increased from 0 to Subject Gender Onset  5, and the SIR score was raised from 1 to 2 after six months of implantation (Figure 2).

m.A7445G
For case 39, profound hearing loss was detected at half years old and later diagnosed as AN.Genetic testing revealed m.A7445G in homoplasmic status, with no other variant related to hearing loss detected in this case.This variant was inherited from the mother, whose hearing was normal.The maternal grandmother of Proband had normal hearing but palmar keratoderma on the left hand (Figure 2).The m.A7445G variant was identified as the molecular cause of hearing loss of the Proband.After four years of implantation, the CAP score was raised from 0 to 7, and the SIR score increased from 1 to 5.

ACTG1
Severe hearing loss was found at one year old in case 74, and no other obvious abnormalities were found till this report when this case was 13 years old.A likely pathogenic de novo variant in ACTG1 was identified by Trio exome sequencing as the cause of this disease, and no other variant leading to hearing loss was revealed in this patient.After seven years of implantation, the average hearing threshold improved from 70.25 dB to 43.75 dB, the CAP score increased from 2 to 5, and the SIR score was raised from 1 to 2.

The copy-number variant
Trio exome sequencing found a pathogenic de novo CNV to be a possible cause of AN in case 56 (hearing levels of this patient's parents are normal).In addition, three variants with uncertain significance were also detected in this patient, including c.3041C>T in MYO7A (NM_000260.3),c.1007G>T in USH1C (NM_001297764.1), and c.1461G>T in PDZD7 (NM_001195263.1), which was inherited from father, mother, mother of this patient, respectively.Profound hearing loss was observed when case 56 was one year old, and the parents of this case reported no other abnormalities until this report.After four years of implantation, the average hearing threshold improved from 97.75 dB to 30 dB after implantation of half years.The CAP score was increased from 0 to 7, and the SIR score was raised from 1 to 5.

Candidate impact factors on speech performances after cochlear implantation
In this study, based on SIR score (n = 74) before and after CI, candidate impact factors on speech performances attributed to CI were analyzed, including the age of onset, age of implantation, with or without risk factors, with or without CN deficiency, bilateral or unilateral implantation, etc. (Figure 3).As we observed, no significant difference in the speech capabilities was observed between subjects with implantation age younger or older than 3 years of age (p = 0.671), subjects with an interval time between onset age and implantation age less or more than three years (p = 0.502), subjects with or without risk factors (p = 0.925), and subjects with bilateral or unilateral implantation (p = 0.394); while speech outcomes of patients with no CN deficiency were better than those of subjects with CN deficiency (p = 0.008).As for subjects with prelingual and post-lingual hearing loss, there was no significant difference in speech outcomes after CI (p = 0.260), but for speech performances before IC, patients with postlingual onset were better than that of subjects with prelingual onset (p = 0.002).
Similarly, 46 patients participating in the genetic testing had no significant difference in speech outcomes between subjects with or without positive genetic etiology (p = 0.597).Furthermore, there was no significant difference in speech performance for subjects with OTOF variants and subjects with remaining genetic lesions (p = 0.503).

Outcomes of cochlear implantation in patients with auditory neuropathy
Auditory and speech outcomes of CI in subjects with AN are always the primary issues to be addressed.Though many studies have focused on this topic (Alzhrani et al., 2019;Shearer and Hansen, 2019), it is still difficult for patients or their parents to decide on CI.In this retrospective study, 75 unrelated patients with AN (61 subjects with the prelingual onset and 14 with post-lingual onset) were enrolled to evaluate auditory and speech performances after CI.For both prelingual and post-lingual recipients, there was a significant improvement in hearing and speech performances compared with those at pre-operation, according to the results of hearing threshold, CAP score, and speech audiometry, SIR score.Generally, cochlear implantation is efficient for patients with AN with severe to profound hearing impairment or those who could not benefit sufficiently from hearing aids.

Risk factors
In the present study, CN deficiency was detected in 10 patients.Second, neonatal hyperbilirubinemia was detected in five patients, including two with other disorders.In another patient, bilirubin encephalopathy combined with neonatal RH hemolysis was also detected.This finding confirms the association between hyperbilirubinemia and AN occurrence (Almishaal et al., 2022).Of 10 patients with CN deficiency and 14 patients identified with other risk factors, nine underwent genetic testing, while molecular etiology was identified in none of these patients.In addition, none of the 75 patients underwent CMV screening.As a result, the risk factor of CMV infection was not analyzed here.

Impact factors
Speech performances of the patient subgroup with CN deficiency were significantly poorer than those of the subgroup with no CN deficiency after CI.At the same time, other candidate impact factors evaluated here had no impacts on CI outcomes, indicating that we should be cautious with the decision of CI in patients with CN deficiency.For 25 patients with a positive molecular diagnosis, there was no significant difference in speech outcomes of patients with mutations in OTOF, which was believed to be related to presynaptic pathology, and mutations from the remaining eight genes or CNV, that were thought to be associated with postsynaptic pathology or

Genetic etiology
Saethre-Chotzen syndrome is a rare, dominant condition characterized by craniosynostosis and syndactyly (Pelc and Mikulewicz, 2018).Diagnosis of this syndrome is based on typical clinical manifestations and identification of pathogenic variants in the TWIST1 gene.Sensorineural, conductive, and mixed hearing loss might be identified in this condition (Rosen et al., 2011).However, to our knowledge, hearing loss type of AN had never been reported in this syndrome before, which would now broaden the phenotype spectrum of this disorder.
A variant of m.A7445G in mitochondrial DNA was implicated in sensorineural hearing loss and nonepidermolytic palmoplantar keratoderma, with incomplete penetrance and variable clinical findings (Maász et al., 2008).The severity of hearing loss caused by m.A7445G varied from mild to profound, while onset age ranged from infancy to adulthood (Maász et al., 2008;Matsushima et al., 2018), although m.A7445G was first reported to be related to AN in this study.
ACTG1 gene, encoding γ-actins, is the responsive gene of DFNA20/26 and Baraitser-Winter cerebrofrontofacial syndrome (Verloes et al., 2015;Sorrentino et al., 2021).The characteristic clinical phenotype of DFNA20/26 is progressive post-lingual hearing loss.However, congenital severe isolated hearing loss caused by a variant in ACTG1 was also reported earlier (Lee et al., 2018).Here, case 74 had a likely pathogenic de novo variant in ACTG1 (T126I) was identified.The wild type of this variant was highly conserved among species (Figure 2; Liu et al., 2008).Moreover, the secondary bond between T126 and I122 (present in subdomain 4) and E83 (present in subdomain 1) amino acid residues would change in mutation type, which would reduce the affinity between amino acid chains or subdomains of protein 1 (Figure 2; Liu et al., 2008).
Perrault syndrome characterizes sensorineural hearing loss with or without progressive neurological deficit in both sexes, combined 1 biosig.unimelb.edu.au/mcsm_ppi2/Candidate impact factors on speech outcomes due to cochlear implantation (CI).S 0: number of cases whose SIR score after CI did not improve compared with that before CI; S 1, S 2, S 3, S 4: number of cases in whom speech intelligibility rating (SIR) score after CI was improved by one, two, three, four compared with that before CI, respectively; Whitney U test was applied for significance analysis and statistical significance was defined as **p < 0.01.Wu et al. 10.3389/fnins.2023.1281884Frontiers in Neuroscience 11 frontiersin.orgwith ovarian dysfunction only in females (Fiumara et al., 2004).TWNK is one of the responsive genes of this syndrome.Meanwhile, the molecular etiology of this syndrome was not identified in approximately 60% of the patients (Lerat et al., 2016;Demain et al., 2017).Herein, we present the first report of a Chinese patient with AN associated with Perrault syndrome, further confirming AN as an audiological feature of this syndrome (Ołdak et al., 2017;Forli et al., 2021).In case 58, hearing loss occurred at eight years of age, combined with primary amenorrhea and hypoplasia of the uterus, and the genetic cause could not be revealed by gene testing.This patient was also diagnosed with Perrault syndrome.

Presynaptic and postsynaptic mechanisms of AN
The presynaptic processes of AN encompass both dysfunction and/or loss of inner hair cells, as well as abnormalities in the ribbon synapses in these cells.The postsynaptic mechanisms of AN encompass various pathological conditions, including abnormalities in dendritic nerve terminals, axonal neuropathies, disorders affecting auditory ganglion cells, myelin disorders, hypoplasia of the auditory nerve, and auditory nerve conduction disorders (Rance and Starr, 2015).CI technology is specifically engineered to directly stimulate the auditory nerve, circumventing the signal transmission process between ribbon synapses in inner cells and terminal dendrites of the auditory nerve.The CI outcomes are influenced by the specific locations of malfunction (Shearer and Hansen, 2019).Oxygen deprivation-induced auditory system impairment was linked to inner hair cell dysfunction, and the auditory system's sensitivity to hyperbilirubinemia involved presynaptic terminal deficits and damages in neuronal Ca 2+ homeostasis, while congenital auditory nerve malformation was found in the postsynaptic site (Rance and Starr, 2015;Moser and Starr, 2016).The findings of this study indicate that the outcomes of CI in patients with CN deficiency were poorer than other patients.
Regarding genetic causes, the products of OTOF have been identified as playing a role in the exocytosis process of glutamatergic ribbon synapses.It has been reported that mutations in OTOF can lead to presynaptic synaptopathy (Moser and Starr, 2016).The study findings indicate that patients with OTOF mutations have demonstrated favorable outcomes of CI (Zheng and Liu, 2020).Mutations occurring in the ATP1A3 gene have probably contributed to the development of postsynaptic synaptopathy (Han et al., 2017).The present study has demonstrated that individuals who have AN resulting from ATP1A3 mutations may have potential advantages from CI (the SIR score ≥ 3, or the maximum speech recognition score > 60% after CI).Similarly, it has been reported that two of four CAPOS patients caused by the same mutation as we have identified in this study have markedly benefitted from CI (Tranebjaerg et al., 2018).The study indicated a correlation between mutations in TIMM8A and the degeneration of cochlear, vestibular, and optic neurons (Bahmad et al., 2007).Additionally, patients with mutations in AIFM1 experienced delayed development of cochlear nerve hypoplasia (Zong et al., 2015).TIMM8A and AIFM1 mutation has been identified as potential factors contributing to the development of postsynaptic neuropathy (Shearer and Hansen, 2019).
Nevertheless, as previously documented, three individuals exhibiting mutations in AIFM1 and two patients with TIMM8A mutations all experienced positive outcomes from CI.The precise pathological mechanisms and specific locations of lesions associated with mutations in TWNK, TWIST1, m.A7445G, ACTG1, and the pathogenic CNV in 7p22.1, remain uncertain.CI outcomes are few and documented in individuals who possess mutations in the TWNK and TWIST1 genes, as well as pathogenic CNVs in the 7p22.1 region.Positive outcomes have been obtained in patients with sensory hearing loss attributed to m.A7445G following CI (Love and Bird, 2013), same results have been observed in individual with AN (case 39) in this study as well.Previous reports have indicated that patients with mutations in ACTG1 gene exhibited satisfactory speech performances after CI (Liu et al., 2019).However, in the present case (case 74), the outcomes of CI did not meet the anticipated level of speech recognition.Understanding the specific locations of lesions can provide valuable insights for guiding the therapeutic therapy of AN.

Limitation
A few limitations of this study include the relatively small subject size, especially leading to the small size of some subgroups in the analysis of impact factors on speech performances.The auditory and speech examinations administered to the recruited patients varied due to factors such as their age and hearing and speech abilities and experiences.In the interim, the length of CI among patients varied from six months to nine years, a factor that was considered significant in the context of speech rehabilitation.

Conclusion
In conclusion, 82.67% (62/75) of enrolled patients in the present study could benefit from CI (the SIR score of 3 to 5, or the maximum speech recognition score > 60% after CI).Ten patients were CN deficient whose speech performances after CI were poorer than those who were not CN deficient (p = 0.008).Other risk factors were identified in 14 patients, and the leading factor was neonatal hyperbilirubinemia.Molecular diagnosis was established in 25 (54.35%) of 46 patients participating in the comprehensive genetic testing.

FIGURE 1
FIGURE 1 Auditory and speech outcomes before and after cochlear implantation (CI) in enrolled auditory neuropathy patients.(A) Hearing thresholds of left ears for subjects with prelingual onset determined by behavior audiometry (n = 20).(B) Hearing thresholds of right ears for subjects with prelingual onset (Continued) determined by behavior audiometry.(C) Hearing thresholds of left ears for subjects with prelingual onset determined by the auditory steady-state response (ASSR) (n = 56).(D) Hearing thresholds of right ears for subjects with prelingual onset determined by ASSR.(E) Average aided hearing threshold after CI for subjects with prelingual onset determined by behavior audiometry (n = 30).(F) Hearing thresholds of left ears for subjects with post-lingual onset determined by pure tone audiometry (n = 11).(G) Hearing threshold of right ears for subjects with post-lingual onset determined by Pure tone audiometry (PTA).(H) Average aided hearing threshold after CI for subjects with post-lingual onset determined by PTA (n = 11).(I) Categories of auditory performance (CAP) and speech intelligibility rating (SIR) scores of enrolled subjects before and after CI.Whitney U test was applied for significance analysis, and statistical significance was defined as **p < 0.01.

FIGURE
FIGURE 1 (Continued) DNA samples of families were not available.

FIGURE 2
FIGURE 2 Case 11, 39, 74 caused by molecular etiologies related to AN. (A) Pedigree of case 11 caused by c.309C>A in TWIST.(B) Hearing thresholds of case 11 before and after CI. (C) Pedigree of case 39 caused by m.A7445G in MT-CO1.(D) Palmar keratoderma on the left hand of maternal grandmother of Proband.(E) A de novo variant identified in ACTG1 in case 74 and the high conservation of the base in ACTG1 among species.(F) The variant of p.T126I would impact the secondary bone between T126 and I122, E83, leading to the reduction of affinity between subdomains or amino acid chains (ΔΔG affinity = −0.136kcal/mol).

TABLE 1
Clinical details of 75 patients with AN enrolled in this study.

TABLE 2
Speech recognition rate of subjects after cochlear implantation.

TABLE 3
The molecular causes of 25 diagnosed subjects.at two years old, and he had no other obvious abnormalities until this report.After six months of implantation in the right ear, his average hearing threshold improved from 116.25 dB to 40 dB, his CAP score increased from 0 to 5, and his SIR score increased from 1 to 4. Case 70 was noticed to have hearing loss at two months old, with the molecular diagnosis being established at the age of one year. impairment